NEW YORK (GenomeWeb News) – Consistent with its recent announcement that it would focus its MDS Pharma Services business on early-stage discovery and development services, MDS today said that it has undertaken a renovation and expansion of its discovery pharmacology operations in Taiwan.
The Taiwan site offers services that include molecular, cellular, ADME/DMPK, and in vivo assays for use in identifying lead drug candidates, profiling for selectivity, determining potential adverse effects, evaluating efficacy, and establishing proof of concept. The firm said that it currently offers more than 800 assays.
MDS expects to complete the expansion in 2010. It did not say whether the expanded operations will include new hires.
Last week, MDS said that it would sell its MDS Pharma Services Late Stage operations, which are comprised of Phase II-IV operations and Central Labs. MDS already has signed an agreement to sell its Phase II-IV operations to contract research organization INC Research for $50 million. It is looking for a buyer for its Central Labs business.